Pulse Biosciences (NASDAQ:PLSE) COO Liane Rae Teplitsky Acquires 1,024 Shares

Pulse Biosciences, Inc (NASDAQ:PLSE) COO Liane Rae Teplitsky bought 1,024 shares of the company’s stock in a transaction on Monday, August 31st. The stock was purchased at an average cost of $48.80 per share, with a total value of $49,971.20. Following the completion of the transaction, the chief operating officer owned 3,094 shares in the company, valued at $150,987.20. This represents a 49.47% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Liane Rae Teplitsky also recently made the following trade(s):

• On Tuesday, September 1st, Liane Rae Teplitsky purchased 1,001 shares of Pulse Biosciences stock. The shares were acquired at an average price of $49.95 per share, for a total transaction of $49,999.95.
• On Friday, August 28th, Liane Rae Teplitsky purchased 1,034 shares of Pulse Biosciences stock. The shares were acquired at an average cost of $48.35 per share, for a total transaction of $49,993.90.
• On Wednesday, August 26th, Liane Rae Teplitsky acquired 1,036 shares of Pulse Biosciences stock. The stock was acquired at an average cost of $48.23 per share, with a total value of $49,966.28.

Pulse Biosciences Stock Performance

NASDAQ PLSE opened at $52.68 on Thursday. The firm has a market cap of $3.65 billion, a price-to-earnings ratio of -44.64 and a beta of 1.63. The firm has a 50 day simple moving average of $36.93 and a 200-day simple moving average of $27.60. Pulse Biosciences, Inc has a one year low of $12.56 and a one year high of $54.39.

Pulse Biosciences (NASDAQ:PLSE) last announced its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The business had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. Equities analysts predict that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PLSE has been the topic of a number of recent research reports. Mizuho set a $45.00 price objective on Pulse Biosciences in a research report on Monday, August 10th. Oppenheimer reissued an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Wall Street Zen upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. Needham & Company LLC assumed coverage on Pulse Biosciences in a report on Monday, August 17th. They set a “buy” rating and a $58.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Pulse Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.25.

Institutional Investors Weigh In On Pulse Biosciences

Large investors have recently modified their holdings of the company. BNP Paribas Financial Markets raised its holdings in shares of Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after purchasing an additional 680 shares in the last quarter. Osterweis Capital Management Inc. purchased a new stake in shares of Pulse Biosciences during the 2nd quarter worth $28,000. Tower Research Capital LLC TRC grew its stake in shares of Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after purchasing an additional 2,156 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Pulse Biosciences by 13.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock worth $70,000 after purchasing an additional 619 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in Pulse Biosciences in the second quarter valued at $158,000. 76.95% of the stock is owned by hedge funds and other institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.